These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
953 related articles for article (PubMed ID: 31637953)
21. Tan J; Liu R; Zhu G; Umbricht CB; Xing M Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648 [TBL] [Abstract][Full Text] [Related]
22. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243 [TBL] [Abstract][Full Text] [Related]
23. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Weber M; Kersting D; Riemann B; Brandenburg T; Führer-Sakel D; Grünwald F; Kreissl MC; Dralle H; Weber F; Schmid KW; Herrmann K; Jentzen W; Grafe H; Rischpler C; Theurer S; Bockisch A; Nagarajah J; Fendler WP Clin Cancer Res; 2022 Oct; 28(19):4194-4202. PubMed ID: 35594174 [TBL] [Abstract][Full Text] [Related]
24. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related]
25. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846 [TBL] [Abstract][Full Text] [Related]
27. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF Zeng Q; Deng Y; Zhang L; Wang W Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623 [TBL] [Abstract][Full Text] [Related]
28. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF Fu H; Cheng L; Sa R; Jin Y; Chen L J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877 [TBL] [Abstract][Full Text] [Related]
29. Dabrafenib Versus Dabrafenib + Trametinib in Busaidy NL; Konda B; Wei L; Wirth LJ; Devine C; Daniels GA; DeSouza JA; Poi M; Seligson ND; Cabanillas ME; Sipos JA; Ringel MD; Eisfeld AK; Timmers C; Shah MH Thyroid; 2022 Oct; 32(10):1184-1192. PubMed ID: 35658604 [No Abstract] [Full Text] [Related]
30. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Oh JM; Ahn BC Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657 [TBL] [Abstract][Full Text] [Related]
32. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299 [TBL] [Abstract][Full Text] [Related]
33. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
34. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
36. Effect of BRAF Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787 [TBL] [Abstract][Full Text] [Related]
37. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259 [TBL] [Abstract][Full Text] [Related]
38. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related]